NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. To help speed the commercialization of new therapies, vaccines, diagnostic tests, and other technologies, NIAID funds more than $100 million each year in Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) awards. Both small business programs are currently reauthorized through FY 2017.
The SBIR and STTR awards allow domestic small businesses to engage in research and development with the potential for commercialization. These programs are one of the largest sources of early-stage technology financing in the U.S. and use set-aside funds mandated by Congress to help bridge the gap between basic science and commercialization.
NIAID supports businesses pursuing research in a variety of important areas, including AIDS, influenza, autoimmune disorders, radiation exposure, and diseases such as tuberculosis, hepatitis, and malaria.
For further information on the programs, including policies and Congressional histories, please visit
Last Updated May 08, 2014
Last Reviewed May 08, 2014